Related Experiment Video

Updated: Jun 14, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

Vascular calcification and cardiovascular outcome in dialysis patients: the role of gene polymorphisms

Mario Cozzolino1, Maria Luisa Biondi, Andrea Galassi

  • 1S. Paolo Hospital, Milan, Italy. mariocozzolino@hotmail.com

Blood Purification
|April 2, 2010
PubMed

Insights

Gene polymorphisms are linked to higher mortality in hemodialysis patients. Understanding these genetic factors may improve cardiovascular risk assessment and patient outcomes in chronic kidney disease.

Area of Science:

  • Nephrology
  • Genetics
  • Cardiovascular Medicine

Background:

  • Vascular calcification and atherosclerosis are leading causes of death in hemodialysis (HD) patients.
  • Uremic conditions involve epigenetic gene regulation, increasing cardiovascular risk.
  • Gene promoter polymorphisms are associated with coronary artery calcification and outcomes in HD patients.

Purpose of the Study:

  • To review gene polymorphisms as prognostic risk factors for mortality in hemodialysis patients.
  • To explore the role of epigenetics in cardiovascular complications in uremic patients.
  • To identify genetic markers independent of traditional risk factors for mortality.

Main Methods:

  • Review of existing literature on gene polymorphisms and mortality in hemodialysis.
  • Analysis of studies linking specific gene variants to cardiovascular outcomes.
  • Examination of epigenetic mechanisms in the context of uremia.

Main Results:

  • Certain gene polymorphisms act as negative prognostic risk factors for all-cause mortality.
  • These genetic factors are independent of traditional cardiovascular risk factors.
  • Polymorphisms influence cellular behavior in uremic conditions, impacting mortality risk.

Conclusions:

  • Gene polymorphisms are significant predictors of mortality in hemodialysis patients.
  • Understanding these genetic associations can enhance risk stratification.
  • Further research into epigenetic mechanisms is crucial for improving outcomes in HD patients.

More Related Videos

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro11:30

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

Analysis of Extracellular Vesicle-Mediated Vascular Calcification Using In Vitro and In Vivo Models09:01

Analysis of Extracellular Vesicle-Mediated Vascular Calcification Using In Vitro and In Vivo Models

Published on: January 27, 2023

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...